Viewing nowCombinationDanumet Film-coated Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharmaceutical Co., Ltd.

MFDS item code 202300832 · Approved 2023.03.13 · Insurance code 059001200
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in combination with sitagliptin and metformin to help patients with type 2 diabetes effectively control their blood sugar. It is used as an adjunct to dietary and exercise therapy to improve blood sugar management.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication is a diabetes treatment that contains both sitagliptin and metformin. Severe allergic reactions may occur during treatment; if symptoms such as rash, itching, or difficulty breathing appear, stop taking the medication immediately and consult a physician. Severe adverse effects such as acute pancreatitis have been reported, so seek immediate medical attention in case of symptoms like abdominal pain, nausea, or vomiting. Patients with severely decreased renal function, acute heart failure, severe infections, or dehydration should not take this medication due to potential risks. Temporarily discontinue this medication before and after tests using iodinated contrast agents, and resume only after renal function is confirmed to be normal. It is safe for pregnant women or those who may become pregnant, as well as nursing mothers, to not take this medication. Be cautious of hypoglycemic symptoms while taking this medication, particularly if used in conjunction with insulin or sulfonylureas, as the risk of hypoglycemia is increased. Patients with impaired liver function or those who consume alcohol excessively are at risk of developing serious metabolic disorders such as lactic acidosis, so caution is required. Regular kidney function and blood tests are necessary, and vitamin B12 deficiency may occur, necessitating supplementation if needed. Patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume only after confirming normal renal function post-surgery. This medication has not established safety and efficacy in children, and it is recommended that not to be administered to pediatric patients under 18 years of age. Elderly patients may be at risk of decreased renal function, so dosage adjustment and regular renal function testing are required. In case of overdose, seek immediate medical attention for appropriate treatment, and the medication can be removed through blood dialysis. Throughout the treatment with this medication, maintaining regular meals and exercise, along with regular blood glucose and blood tests, is crucial for effective management.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air exposure and kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and ensure its safe use.
Oval coated tablet with reddish brown color
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.